Egle Avizienyte
Knutsford, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial.
Journal: BMC medicine
Published: October 07, 2021
Synthetic Site-Selectively Mono-6-O-Sulfated Heparan Sulfate Dodecasaccharide Shows Anti-Angiogenic Properties In Vitro and Sensitizes Tumors to Cisplatin In Vivo.
Journal: PloS one
Published: April 21, 2016
Synthetic heparan sulfate dodecasaccharides reveal single sulfation site interconverts CXCL8 and CXCL12 chemokine biology.
Journal: Chemical communications (Cambridge, England)
Published: August 04, 2015
The development of anti-angiogenic heparan sulfate oligosaccharides.
Journal: Biochemical Society transactions
Published: November 18, 2014
Ovarian cancer cell heparan sulfate 6-O-sulfotransferases regulate an angiogenic program induced by heparin-binding epidermal growth factor (EGF)-like growth factor/EGF receptor signaling.
Journal: The Journal of biological chemistry
Published: February 25, 2014
Tetrasaccharide iteration synthesis of a heparin-like dodecasaccharide and radiolabelling for in vivo tissue distribution studies.
Journal: Nature communications
Published: October 13, 2012
Endothelial heparan sulfate 6-O-sulfation levels regulate angiogenic responses of endothelial cells to fibroblast growth factor 2 and vascular endothelial growth factor.
Journal: The Journal of biological chemistry
Published: August 29, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026